Pfizer : Quarterly Corporate Performance - First Quarter 2024 Infographic

First Quarter 2024

Earnings

Highlights

$14.9B	$0.55		$0.82
	Revenue
-19% Op1 Decline	Rep. Dil. EPS2		Adj. Dil. EPS2,3
			-44%		-32%
+11% Op Growth excl.
Decline		Op Decline
COVID-19 products

$2.4B

Cash Dividends Returned

to Shareholders

$0.42 Per Share

of Common Stock

$2.5B	Revenue
$58.5B-$61.5B
Rep. R&D	FY 2024 Guidance4
Expenses	$2.15-$2.35
	Adj. Dil. EPS3

"

I am encouraged by a well-executed quarter, setting the tone for the year. Pfizer's commercial leadership is focused on data-driven opportunities across several key growth brands, both in the U.S. and internationally, and we intend to build on this positive momentum in the quarters ahead."

Albert Bourla

Chairman and Chief Executive Officer

First-Quarter 2024 Global

Pharmaceutical Revenues

Primary CareSpecialty CareOncology

$7.2B Revenue	$3.8B Revenue	$3.5B Revenue
-37% Op Decline	+7% Op Growth	19% Op Growth

Key Revenue Growth Drivers

Legacy

Portfolio

Family5

6

7

Family

Pipeline Spotlights8

Prevention of invasive disease,

Approved in EU pneumonia and acute otitis media caused by Streptococcus pneumoniae in individuals from

6 weeks to less than 18 yrs.

	Treatment of serious infections
Approved in EU	in adult patients caused by
Emblaveo®	multidrug-resistantGram-negative
bacteria, including metallo-β-
	lactamase-producing bacteria.

EU regulatory filing for treatment of adults with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.

Positive Phase 3 top-line results in adults 60+ yrs following a second season from ongoing trial.

	Treatment of moderately to
Approved in EU	severely active ulcerative colitis in
patients 16+ yrs who have had an
	inadequate response, lost response,
	or were intolerant to conventional
	therapy or a biological agent.
	Treatment of adults with moderate to
	severe hemophilia B who currently use
	factor IX prophylaxis therapy, or have
Approved in U.S.	current or historical life-threatening
BEQVEZ™	hemorrhage, or have repeated,
serious spontaneous bleeding
	episodes, and do not have neutralizing
	antibodies to adeno-associated virus
	serotype Rh74var capsi.
	Positive Phase 3 overall survival
	results for treatment of patients
	with relapsed/refractory diffuse
	large B-cell lymphoma as
	combination therapy.
	Positive Phase 3 top-line results
	in adults 18-59 yrs. at risk of
	developing severe respiratory
	syncytial virus-associated lower
	respiratory tract disease.

>119M

Patients

Impacted

YTD Q1 2024 with our medicines and vaccines9

2024 Key Priorities

Focused on executing with excellence against strategic goals to drive long-term growth

Achieve	Deliver	Maximize	Expand	Allocate
world-class	next wave	performance of	margins by	capital to enhance
oncology	of pipeline	new products	realigning	shareholder
leadership	innovation		cost base	value

What's Next

Remains confident in ability to deliver operational growth and

meaningful shareholder value long term.

Maintain	Scale
patient	emerging tech
centricity	platforms
	Invest
	in areas
	we can win

Foster	Reduce
a culture of	approval development
innovation	cycle times

ANTICIPATES

Non-COVID 2024 operational revenue growth of 8% to10%10

investors.pfizer.com

Please reference Pfizer's Q1 2024 earnings release and SEC filings for additional information.

1. Reference to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates.
2. First-quarter2024 Reported and Adjusted diluted EPS were favorably impacted by $0.11 resulting from a $771 million final adjustment to the estimated non-cash Paxlovid revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, reflecting 5.1 million of EUA-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated 6.5 million treatment courses that were expected to be returned as of December 31, 2023.
3. Adjusted income and Adjusted diluted EPS are defined as U.S. GAAP net income attributable to Pfizer Inc. common shareholders and Reported diluted EPS attributable to Pfizer Inc. common shareholders before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items. See the reconciliations of certain GAAP Reported to Non-GAAP Adjusted information for the first quarter of 2024 and 2023 accompanying Pfizer's earnings release furnished with Pfizer's
   Current Report on Form 8-K dated May 1, 2024. Adjusted income and its components and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. See the Non-GAAP Financial Measure: Adjusted Income section of Management's Discussion and Analysis of Financial Condition and Results of Operations in Pfizer's 2023 Annual Report on Form 10-K and the Non-GAAP Financial Measure: Adjusted Income section accompanying Pfizer's earnings release furnished with Pfizer's Current Report on Form 8-K dated May 1, 2024, for additional information.
4. Total company guidance. Please see Pfizer's Q1 2024 earnings release for additional details and assumptions regarding Pfizer's 2024 financial guidance.
5. Vyndaqel family includes global revenues from Vyndaqel, as well as revenues for Vyndamax in the U.S. and Vynmac in Japan.
6. Primarily reflects alliance revenues and product revenues.
7. Prevnar family includes revenues from Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult).
8. Pipeline updates as of May 1, 2024.
9. The Patients Impacted metric is calculated from Pfizer and third-party datasets. Figures may be limited given the coverage provided by external sources (e.g., calendar duration, geographic and product coverage) and are subject to change. Numbers are estimates and in some cases use global volume, daily dosage and number of treatment days to facilitate calculations. Methodologies to calculate estimates may vary by product type given the nature of the product and available data. Patients taking multiple Pfizer products may be counted as multiple patients towards total. Numbers do not include comprehensive estimated patient counts from Ex-U.S. Access
   & Affordability programs. Historical estimates may periodically be subject to revision due to restatements in the underlying data source.
10. Please see Pfizer's press release issued on December 13, 2023, as well as Pfizer's Q1 2024 earnings release for additional details and assumptions regarding Pfizer's 2024 financial guidance.

This document includes forward-looking statements about, among other things, Pfizer's anticipated operating and financial performance, including financial guidance and projections, product pipeline, in-line products and product candidates, product launches, revenue contributions, business plans, strategy, goals and prospects, growth potential, business development activities, manufacturing and product supply, capital allocation objectives, dividends and share repurchases that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Please refer to Pfizer's Annual Report on Form 10-K for the year ended December 31, 2023, and its subsequent reports on Form 10-Q, including the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results," as well as Pfizer's subsequent reports on Form 8-K for a description of the substantial risks and uncertainties related to the forward-looking statements included in this document. These reports are available on Pfizer's website at www.pfizer.comand on the U.S. Securities and Exchange Commission's website at www.sec.gov. The forward-looking statements in this document speak only as of the original date of this document, and we undertake no obligation to update or revise any of these statement.

© 2024 Pfizer Inc. All rights reserved.